Consistent with this, in preclinical work, endocrine-resistant and ESR1-MUT breast cancer cells retain palbociclib sensitivity, and PDX models with ESR1-MUT also remain sensitive to palbociclib and abemaciclib [33, 37, 60]. This evidence concerns the gene ESR1 and breast cancer.